Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson’s nearly two decades of innovation in the disease area Lead asset shows potential ...
Johnson & Johnson MedTech announced today that it submitted its Ottava surgical robotic system to the FDA for de novo ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, however, committed to progressing its remaining pipeline of candidates for ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback